Date published: 2025-10-11

00800 4573 8000

SCBT Portrait Logo
Seach Input

VSIG (V-set and immunoglobulin domain containing) Inibidores

The V-set and Immunoglobulin Domain Containing (VSIG) family is a group of proteins characterized by the presence of V-set and immunoglobulin (Ig) domains. These domains are typically found in molecules involved in immune system functioning and cell adhesion. This family is currently comprised of eight members, including VSIG1, VSIG2, VSIG3, VSIG4, VSIG8, VSIG9, VSIG10, and VSIG10 L, which are all type I transmembrane proteins. Members of the VSIG family are predominantly expressed in the immune system and various epithelial tissues, suggesting a role in immune responses and epithelial cell interactions. The function of VSIG proteins often involves cell-cell adhesion, signaling, and modulation of immune responses, although the specific roles can vary among different family members. In terms of signaling, VSIG proteins are known to participate in a variety of pathways, including those that regulate cell proliferation, differentiation, and apoptosis, particularly in the context of immune and epithelial cells. Furthermore, some VSIG family members have been implicated in the development and progression of certain cancers, indicating their potential as targets or biomarkers in oncology.

Targeting V-set and Immunoglobulin Domain Containing (VSIG) proteins using small molecules can provide valuable insights into the mechanistic aspects of T-cell responses and immune suppressive microenvironments. VSIG proteins are implicated in immune cell interactions and signaling pathways that are crucial for the regulation of T-cell activity and immune tolerance. By disrupting or inhibiting VSIG proteins, researchers can observe changes in T-cell behavior, helping to elucidate their role in immune activation and suppression.

VEJA TAMBÉM

Nome do ProdutoCAS #Numero de CatalogoQuantidadePrecoUso e aplicacaoNOTAS

AZD7762

860352-01-8sc-364423
2 mg
$107.00
(1)

Inibidor potente tanto da CHK1 como da CHK2, utilizado em estudos pré-clínicos para o cancro. Inibidores da quinase do ponto de verificação (CHK) que afectam potencialmente os mecanismos de controlo do ciclo celular nos quais as proteínas VSIG podem desempenhar um papel.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

inibidor de MEK, poderia interferir com as vias de sinalização MAPK/ERK relacionadas com o VSIG.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

inibidor da JNK, que pode afetar as vias de resposta ao stress relacionadas com o VSIG.

LY2606368

1234015-52-1sc-507521
sc-507521A
sc-507521B
sc-507521C
sc-507521D
sc-507521E
5 mg
10 mg
25 mg
100 mg
1 g
10 g
$176.00
$300.00
$500.00
$1900.00
$8000.00
$25000.00
(0)

Um inibidor seletivo da CHK1, que está a ser investigado em ensaios clínicos para vários tipos. Inibidores da quinase do ponto de verificação (CHK) que afectam potencialmente os mecanismos de controlo do ciclo celular, nos quais as proteínas VSIG podem desempenhar um papel.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

inibidor da p38 MAPK, poderia modificar as vias de resposta inflamatória relacionadas com o VSIG.

PF 477736

952021-60-2sc-362781
sc-362781A
5 mg
25 mg
$113.00
$423.00
(1)

Um inibidor potente e seletivo da CHK1 Inibidores da quinase do ponto de verificação (CHK) que afectam potencialmente os mecanismos de controlo do ciclo celular nos quais as proteínas VSIG podem desempenhar um papel.

SCH 900776

891494-63-6sc-364611
sc-364611A
5 mg
10 mg
$255.00
$338.00
(0)

Um inibidor seletivo da CHK1, foi investigado em ensaios clínicos Inibidores da quinase do ponto de verificação (CHK) que afectam potencialmente os mecanismos de controlo do ciclo celular nos quais as proteínas VSIG podem desempenhar um papel.